Condition category
Digestive System
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Ulcerative colitis (UC) is a form of inflammatory bowel disease. It is a long-term condition that results in ulcers on the internal surface of the bowel which can bleed and produce pus. Symptoms of the disease include diarrhoea (which may contain blood, mucus and/or pus), abdominal pain and an increase in the need to use the toilet. Patients can go for months with no, or very mild, symptoms (remission) and then suffer a flare up (relapse) where symptoms become much more severe; hospital treatment can become necessary in the worse cases. Most UC patients remain on long-term medication to maintain their lifestyle and prevent flare-ups of disease. Even so, over one third of patients who have had a flare-up of their disease will suffer from another attack within the following twelve months. If this happens, many will need to take more medication, including taking steroids. These flare-ups also effect patients' ability to work and look after children, as well as on their overall quality of life. Doctors are constantly looking for new ways to manage the condition, including developing new drugs to try to prevent or limit disease flare-ups. There is some evidence that the appendix has a role in the regulation of inflammation within the bowel, and that removing the appendix may have a positive impact on how active UC is. This evidence is not yet strong enough to recommend that all patients with UC would benefit from having their appendix removed. We feel that this is an interesting and exciting potential treatment option, and aim to explore it further within this research. Here, we want to find out whether removing the appendix (appendicectomy) can reduce the chances of UC flare-ups. We are going to look at whether it's an attractive treatment to offer to UC sufferers, both from the patients' and the doctors' point of view. If we can successfully recruit patients to this trial, and review them regularly throughout the one year period afterwards, we plan to undertake a follow-on trial in the future to establish exactly how beneficial this treatment is in a larger group of UC patients.

Who can participate?
Adult patients (aged at least 18) that have been diagnosed with UC, currently in remission but have had a disease flare-up within the last 12 months.

What does the study involve?
Firstly, patients undergo a camera examination (endoscopy) of their colon to conform that their UC is currently in remission. Then, having filled in questionnaires on their symptoms and disease activity, they are randomly allocated into one of two groups, the appendicectomy group or the control group. Those in the control group take their standard tablet medication as usual.Those in the appendicectomy group also take their usual medication but they also undergo a appendicectomy. After this stage, regardless of which group patients are in, the follow-up is the same. This involves regular reviews in the outpatient clinic, where the doctor and/or the research team discuss current symptoms and complete further questionnaires. These reviews take place around 6 weeks (appendicectomy group only), 3, 6, 9 and 12 months after entry to the trial. Any patient's medication can be changed or increased during the trial period if felt necessary by the medical team. All medication use is documented during the trial period, and notes made on any other effects of the disease patients suffer, such as time off work or days where patients are unable to function as they would like to. At the end of the trial, a further camera examination of the patient's bowel takes place. As part of the ACCURE-UK trial patients may also be asked to take part in a discussion (research interview) with a researcher from the ACCURE-UK team. These discussions help the team understand what it is like for patients to take part in the study, and help us to make sure that these perspectives influence the design of any follow on trial.

What are the possible benefits and risks of participating?
If allocated to the appendicectomy group and the operation does prove to have an impact on the disease activity in UC, there may be a potential benefit to an individual patient in taking part in terms of reducing the number or severity of disease flare-ups. This may in turn impact upon the future use of medication, number of hospital admissions and the need for major bowel surgery. If allocated to the control group, there is unlikely to be any personal benefit from taking part in the trial, although patients will undergo a period of careful disease medical treatment and monitoring. Some patients will draw satisfaction from the knowledge that their involvement, in either group, will help determine if this new proposed treatment has the potential to benefit all patients affected by UC. However it is important to note that like any surgery there is always the possibility of complications. We have done our best to reduce the chances of these by ensuring that only experienced and specialised colorectal consultant surgeons undertake operations during the trial.

Where is the study run from?
1. Queen Elizabeth Hospital
2. Heartlands Hospital
3. Good Hope Hospital Sutton Coldfield
4. University Hospital of North Tees
5. Leicester General Hospital
6. St Mark's Hospital
7. Walsall Manor Hospital
8. University Hospital of Hartlepool

When is the study starting and how long is it expected to run for?
December 2014 to December 2016

Who is funding the study?
NIHR Research for Patient Benefit (UK)

Who is the main contact?
Miss Rebecca Howard

Trial website

Contact information



Primary contact

Miss Rebecca Howard


Contact details

B15 2TT
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE colitis - The ACCURE UK Trial Feasibility Study: a randomised clinical trial


ACCURE-UK Feasibility Study

Study hypothesis

The ACCURE-UK feasibility study is a 48 patient feasibility with the aim of establishing whether an appendicectomy operation for the treatment of UC is an acceptable option. If appendicectomy is an acceptable treatment option for UC patients and clinicians, a major randomised trial to explore clinical efficacy will be undertaken.

Ethics approval

Tyne and Wear South Ethics Committee, 24/10/2014, ref. 14/NE/1143

Study design

Randomised; Interventional; Design type: Treatment

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet


Topic: Surgery, Gastroenterology; Subtopic: Surgery, Gastroenterology; Disease: All Surgery, All Gastroenterology


24 patients will be randomised to the control (standard medical therapy), 24 patients will be randomised to the intervention (appendicectomy) plus standard medical therapy.

The intervention is the removal of the appendix as a treatment for ulcerative colitis alongside standard medical therapy.

Follow Up Length: 12 month(s)

Intervention type



Drug names

Primary outcome measures

1. Acceptability of the intervention. Timepoint(s): Baseline, 6 weeks post surgery and 12 months post-randomisation.

Secondary outcome measures

1. Determine the suitability of the QoL outcome measures. Timepoint(s): Analysis of suitability will be after all the collection time-points (>12months)
2. Estimate the morbidity profile of the appendicectomy operation. Timepoint(s): Data will be collected 6 weeks post-surgery
3. Patient-related outcomes e.g. disease-related work absence and loss of earnings. Timepoint(s): 6 weeks post randomisation, 3, 6, 9 & 12 months post randomisation
4. Relapse rate in the control arm. Timepoint(s): This will be collected throughout the trial, at 3, 6, 9 & 12 months;
5. Test the one-year follow-up strategy for the future phase III trial. Timepoint(s): Basline, 6 weeks post surgery, 3, 6, 9 & 12months post randomisation
6. The numbers of eligible, approached and randomised patients. Timepoint(s): During recruitment phase only- 6 months

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

The target population for this study is adults with established and recently active UC. The inclusion criteria are as follows:
1. Histologically confirmed UC
2. Disease relapse within 12 months of randomisation
3. In clinical remission at time of randomisation with clinical Mayo score less than 3 and endoscopic Mayo score of 0 or 1
4. Aged at least 18
5. Able and willing to give written informed consent
6. Male & Female

Participant type


Age group




Target number of participants

Planned Sample Size: 48; UK Sample Size: 48

Participant exclusion criteria

1. Previous appendicectomy
2. Previous major abdominal surgery which would preclude safe laparoscopic appendicectomy
3. Uncertain histological findings and any suspicion of Crohn's disease
4. Infective diarrhoea
5. Severe ongoing colitis at time of randomisation
6. Patients with significant comorbidity (eg unstable heart failure)
7. Enrollment in other trial of any novel treatment (including drugs or other interventions) for UC within preceding 6 months
8. Under the age of 18
9. Unable/unwilling to provide informed consent

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Queen Elizabeth Hospital
B15 2TH
United Kingdom

Trial participating centre

Heartlands Hospital
B9 5SS
United Kingdom

Trial participating centre

Good Hope Hospital
B75 7RR
United Kingdom

Trial participating centre

University Hospital of North Tees
TS19 8PE
United Kingdom

Trial participating centre

Leicester General Hospital
United Kingdom

Trial participating centre

St Mark's Hospital
United Kingdom

Trial participating centre

Walsall Manor Hospital
United Kingdom

Trial participating centre

University Hospital of Hartlepool
TS24 9AH
United Kingdom

Sponsor information


University of Birmingham (UK)

Sponsor details

B15 2TT
United Kingdom

Sponsor type




Funder type


Funder name

NIHR Research for Patient Benefit (RfPB); Grant Codes: PB-PG-1112-29107

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2015 protocol in:

Publication citations

Additional files

Editorial Notes

22/06/2015: the overall trial end date was changed from 01/06/2015 to 01/12/2016.